Life Sciences

  • March 31, 2026

    Insurer Says Yale Was 'Misleading' In $4.1M Transplant Claim

    A Liberty Mutual unit accused Yale University's health system of making "serious and material misstatements" about a plan member's bone marrow transplant, the insurer said in its answer and counterclaim for a declaratory judgment that it can continue to deny the $4.1 million claim.

  • March 31, 2026

    Kirkland, Goodwin Steer Lilly's $7.8B 'Sleep-Wake' Disorder Deal

    Pharmaceutical giant Eli Lilly & Co., advised by Kirkland & Ellis LLP, on Tuesday announced plans to acquire daytime sleepiness-focused pharmaceutical company Centessa Pharmaceuticals PLC, led by Goodwin Procter LLP, in a deal worth up to $7.8 billion.

  • March 31, 2026

    Cancer Vaccine Developer Files Ch. 7 After Trials Fall Short

    A Denmark-based biotechnology firm filed for Chapter 7 liquidation Tuesday in Delaware with more than $10 million in debt after its prospective cancer vaccine failed to measure up under testing and win regulatory approval last year.

  • March 30, 2026

    Don't Set Special IP Rules For 'Skinny Labels,' Justices Told

    Drugmakers, industry groups, hospitals and scholars have urged the U.S. Supreme Court to uphold a decision letting a patent suit proceed over a generic drug using a so-called skinny label, saying the generics company is seeking unwarranted special protections that would upend patent law.

  • March 30, 2026

    FCA Qui Tams Are Unconstitutional, Eli Lilly Tells Justices

    The False Claims Act's whistleblower provisions are unconstitutional, drugmaker Eli Lilly has told the U.S. Supreme Court, asking it to overturn a Seventh Circuit decision upholding a $183 million trial win for a whistleblower who claimed the drug company hid how much it charged for Medicaid-covered drugs. 

  • March 30, 2026

    Sanofi Claims IP Life Extension Needed For Double Patenting

    The Patent Trial and Appeal Board rightly found a Sanofi patent application shouldn't be rejected for obviousness-type double patenting, as it doesn't improperly extend patent life, the French drugmaker and its allies have told U.S. Patent and Trademark Office Director John Squires.

  • March 30, 2026

    Cleary-Led Blackstone Wraps Record $6.3B Life Sci Fund

    Private equity giant Blackstone, led by Cleary Gottlieb Steen & Hamilton LLP, revealed Monday that it wrapped its sixth life sciences fund after securing $6.3 billion of capital commitments, marking what the firm says is the largest private life sciences fund ever raised.

  • March 30, 2026

    Eli Lilly's $2.75B Pact Is Latest In AI Drug Discovery Push

    Eli Lilly and Co. has agreed to a partnership with artificial intelligence-driven drug discovery company Insilico that could be worth up to $2.75 billion, amid an expanding category of collaboration fueled by pharmaceutical giants seeking accelerated paths to new treatments. 

  • March 30, 2026

    Del. Judge Upholds $34M Verdict In Glaucoma Patent Feud

    A Delaware federal judge has affirmed a $34 million verdict against Alcon and related entities for infringing patents covering medical devices to treat glaucoma, disagreeing that Sight Sciences Inc. had failed to show the accused product meets the limitations of the patent claims.

  • March 30, 2026

    J&J Unit Wants Forensic Exam Of Ex-Director's Devices

    A Johnson & Johnson subsidiary urged a New Jersey federal court to order a former associate director to submit to a court-supervised forensic inspection of any device or account in which she could have stored confidential information it claims she downloaded in order to start her own competing company.

  • March 30, 2026

    Eagle Pharma To Pay $9.5M To End Channel Stuffing Claims

    Eagle Pharmaceuticals Inc. and its former executives have agreed to pay $9.5 million to settle investor claims that they carried out a fraudulent "channel stuffing" scheme to inflate the revenue of one of the company's brand-name medications.

  • March 30, 2026

    High Court Turns Away CRISPR Patent Validity Dispute

    The U.S. Supreme Court on Monday rejected Agilent Technologies' bid to revive patents on the gene-editing tool CRISPR, which centers on the burden of proof in establishing prior art.

  • March 30, 2026

    Justices Pass On FCA Suit Alleging Quest Diagnostics Fraud

    The U.S. Supreme Court rejected on Monday a former Quest Diagnostics Inc. compliance officer's bid for review of the dismissal of a long-running False Claims Act suit against the medical testing company.

  • March 30, 2026

    Justices Reject TM Appeal Tied To 'Use In Commerce'

    The U.S. Supreme Court on Monday declined to take up an appeal challenging a Ninth Circuit ruling that upheld a multimillion-dollar default judgment based largely on statements defendants made in trademark applications.

  • March 27, 2026

    Elizabeth Holmes Gets 11-Year Prison Sentence Cut By A Year

    A California federal judge has shaved off a year from convicted ex-Theranos CEO Elizabeth Holmes' 11-year-and-three-month prison sentence for securities fraud due to recent sentencing guideline amendments, reducing her time behind bars by one year, instead of the two years she requested, amid objections by prosecutors.

  • March 27, 2026

    Eli Lilly Keeps Most Of Weight Loss Drug Copy Suit Alive

    A California federal judge has refused to throw out a lawsuit accusing a pair of telehealth companies of making copies of Eli Lilly's obesity and type 2 diabetes drugs but agreed to trim the case.

  • March 27, 2026

    Del. Justices Won't Revive Hedge Fund Insider Trading Case

    The Delaware Supreme Court upheld a ruling Friday in favor of hedge fund Armistice Capital, backing the dismissal of a lawsuit accusing the firm of insider trading on information it had obtained in its position as a minority stakeholder of a pharmaceutical company.

  • March 27, 2026

    Hospital System Beats Most Of REIT's $50M Floodwall Suit

    A New York federal judge on Friday mostly tossed a real estate investment trust's $50 million suit against the New York City Health and Hospitals Corp. and the NYC Economic Development Corp. over the design of a proposed floodwall for a downtown Manhattan life sciences campus project.

  • March 27, 2026

    Nobel Prize Winners Again Lose Patent Fight Over CRISPR

    The Patent Trial and Appeal Board has ruled against a pair of Nobel Prize-winning scientists in a patent dispute over who was the first to invent key aspects of the gene-editing technology CRISPR, siding again with a rival team from the Broad Institute and the Massachusetts Institute of Technology.

  • March 27, 2026

    Skincare Co. Says ITC Ruling Backs Ending PTAB Challenge

    Skin products company Hydrafacial has argued U.S. Patent and Trademark Office Director John Squires should turn down a rehearing request from rival Sinclair Pharma over Squires' order de-instituting a challenge to Hydrafacial's patent, saying a U.S. International Trade Commission decision upholding the same patent supports the director's move.

  • March 27, 2026

    Sens. Push Bill To Equip VA For Psychedelic Therapies

    A bipartisan group of U.S. senators has introduced legislation to broaden veterans' access to emerging therapies, including psychedelic-assisted treatments, that may be effective in addressing post-traumatic stress disorder and other mental health issues.

  • March 27, 2026

    Biopharma's Brass Hid Anxiety Drug Trial Risks, Investor Says

    Vistagen Therapeutics' current and former top brass have been hit with a derivative shareholder suit in California federal court alleging they overstated its clinical trial for a novel, anti-anxiety drug while hiding unpredictable placebo responses and other known risks, before the phase ultimately failed, causing a stock price collapse. 

  • March 27, 2026

    Biogen Beats Investor Suit Over Dozens Of Drug Claims

    Biogen Inc. and four of its executives escaped a stock drop suit Friday after a Massachusetts federal judge ruled that none of the nearly five dozen statements challenged by investors suggested that the company intentionally misled people buying its stock.

  • March 27, 2026

    Mississippi Gov. Vetoes Medical Marijuana Expansion Bill

    Mississippi Gov. Tate Reeves has vetoed a bill to expand the state's medical cannabis program to include severely ill patients, while approving another bill to fund a clinical trial into the psychedelic ibogaine.

  • March 27, 2026

    NJ Federal Judge DQs Beasley Allen In J&J Talc MDL

    A New Jersey federal judge has disqualified the Beasley Allen Law Firm from representing hundreds of plaintiffs in sprawling multidistrict litigation over Johnson & Johnson's talc-based baby powder, holding that the firm violated ethics rules by collaborating with former outside counsel for J&J, a ruling the law firm has vowed to appeal.

Expert Analysis

  • Getting The Most Out Of Learning And Development Programs

    Excerpt from Practical Guidance
    Author Photo

    Junior associates can better develop the legal, business and interpersonal skills they need for long-term success by approaching their firms’ learning and development programs armed with five tips for getting the most out of these resources, says Lauren Hakala at Reed Smith.

  • Opinion

    AI Presents A Make-Or-Break Moment For Outside Counsel

    Author Photo

    The rapid adoption of artificial intelligence by corporate legal departments is forcing a long-overdue reset of the relationship between inside and outside counsel, and introducing a significant opportunity to shed frustrating inefficiencies and strengthen collaboration for firms willing to embrace the shift, says Intel Chief Legal Officer April Miller Boise.

  • Opinion

    USPTO Has A Chance To Correct Double-Patenting Doctrine

    Author Photo

    Now that the issue of obviousness-type double patenting is front and center before the U.S. Patent and Trademark Office's Appeals Review Panel, the agency should put an end to the practice of rejecting earlier-expiring patents in favor of later-expiring ones, say attorneys at Orrick.

  • Navigating Life Sciences Deals Amid Heightened Scrutiny

    Author Photo

    With pricing reform initiatives, national security legislation and evolving trade policy currently contributing to meaningful uncertainty for life sciences companies, it is important to proactively structure deals to avoid downstream complications, say attorneys at Cooley.

  • Series

    Watching Hallmark Movies Makes Me A Better Lawyer

    Author Photo

    I realize you may be judging me for watching, and actually enjoying, Hallmark Channel movies, but the escapism and storylines actually demonstrate qualities and actions that lead to an efficient, productive and positive legal practice, says Karen Ross at Tucker Ellis.

  • New Orphan Drug Law Provides A Key Fix For Pharma Cos.

    Author Photo

    The Consolidated Appropriations Act enacted last month restores the U.S. Food and Drug Administration's long-standing interpretation of "same disease or condition," related to orphan drug exclusivity, resolving years of regulatory uncertainty and litigation that have discouraged rare disease research, say attorneys at Spencer Fane.

  • When Trade Secret Litigation And Criminal Law Collide

    Author Photo

    An increasing convergence of trade secret litigation and white collar defense, especially with several recent criminal prosecutions from the Justice Department, should prompt businesses and counsel to adapt within the overlapping landscapes, says Kenneth Notter at MoloLamken.

  • Opinion

    PTAB Needs Reform To Protect Inventors From Larger Cos.

    Author Photo

    The Promoting and Respecting Economically Vital American Innovation Leadership Act is necessary because it will impose additional requirements on patent validity challenges and prevent large corporations from taking advantage of the Patent Trial and Appeal Board to overwhelm small inventors with repeated litigation, says Eb Bright at ExploraMed Development.

  • FDA User Fee Talks Offer Clues On Upcoming Reforms

    Author Photo

    As the U.S. Food and Drug Administration undergoes the User Fee Act reauthorization process and renegotiates its user fee agreements over the next several months, the agency's consultation meetings with relevant industries can shed light on the FDA's priorities, and provides stakeholders an opportunity to participate in the reform process, say attorneys at Holland & Knight.

  • Moderna Case Highlights Overlooked Hurdle In Biopharma IP

    Author Photo

    The recent settlement of the patent litigation involving Moderna's COVID-19 vaccine in Delaware federal court shows that patent portfolios covering enabling platform technologies can create significant freedom-to-operate risk even when their owners are not direct competitors developing the therapeutic product, says Olga Berson at Thompson Coburn.

  • FDA Framework For Personalized Therapies Raises Questions

    Author Photo

    The U.S. Food and Drug Administration's new plausible mechanism framework for developing individualized therapies reflects the agency's focus on rare-disease drugs, but numerous significant, unresolved issues cast uncertainty on how effective the framework will be in practice, say attorneys at Ropes & Gray.

  • Emissions Permits May Not Override Pollution Exclusions

    Author Photo

    Two recent coverage rulings from the Illinois Supreme Court and the Third Circuit suggest a trend among appellate courts to deny coverage under pollution exclusions, even when the emissions happened pursuant to a government permit, say attorneys at Simpson Thacher.

  • 5 Tips For Navigating Your Firm's All-Attorney Summit

    Excerpt from Practical Guidance
    Author Photo

    Law firm retreats should be approached strategically, as they present valuable opportunities to advance both the firm's objectives and attorneys' professional development through meaningful participation, building and strengthening internal relationships, and proactive follow-up, says James Argionis at Cozen O’Connor.

  • Series

    Coaching Soccer Makes Me A Better Lawyer

    Author Photo

    Coaching youth soccer for my 7-year-old son's team has sharpened how I communicate with clients, prepare witnesses, work within teams and think about leadership, making me a more thoughtful and effective lawyer in many ways, says Joshua Holt at Smith Currie.

  • Series

    Law School's Missed Lessons: The Human Element

    Author Photo

    Law school teaches you to quickly apply intellect and logic when handling a legal issue, but every fact pattern also involves a person, making the ability to balance expertise with empathy critical to the growth of relationships with clients, colleagues and adversaries, says Rachel Adcox at Adcox Strategies.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here